Premier downgraded to Underperform with $35 target at Credit Suisse » 06:3401/1501/15/21
Credit Suisse analyst…
Story temporarily locked.
Premier downgraded to Underperform from Neutral at Credit Suisse » 05:1801/1501/15/21
Credit Suisse analyst…
Credit Suisse analyst Jailendra Singh downgraded Premier to Underperform from Neutral with a $35 price target.
|Over a week ago|
Jefferies downgrades Premier to Hold, sees lack of catalysts » 08:0101/0801/08/21
As previously reported,…
As previously reported, Jefferies analyst Brian Tanquilut downgraded Premier (PINC) to Hold from Buy with an unchanged price target of $40. Following a 13% move up in shares since the beginning of October, Tanquilut views the stock as fairly valued and he does not see near-term catalysts for further meaningful upside, he tells investors. Though a recovery in hospital volumes would boost Premier's GPO business, Tanquilut prefers more direct plays in hospitals, such as Tenet Healthcare (THC), which he has upgraded to Buy from Hold this morning.
Premier downgraded to Hold from Buy at Jefferies » 04:5101/0801/08/21
Jefferies analyst Brian…
Jefferies analyst Brian Tanquilut downgraded Premier to Hold from Buy with a $40 price target.
Premier price target raised to $44 from $37 at Canaccord » 15:0801/0701/07/21
Canaccord analyst Richard…
Canaccord analyst Richard Close raised the firm's price target on Premier to $44 from $37 and keeps a Buy rating on the shares. In 2021, he expects to see accelerated adoption of disruptive models in healthcare services and expects demand for next generation companies to remain high, Close tells investors.
Change Healthcare downgraded to Equal Weight from Overweight at Wells Fargo » 13:5601/0701/07/21
CHNG, HMSY, PINC, UNH
Wells Fargo analyst Jamie…
Wells Fargo analyst Jamie Stockton downgraded Change Healthcare (CHNG) to Equal Weight from Overweight with a price target of $25.75, up from $21, after the company agreed to be acquired by UnitedHealth (UNH) for $25.75 cash per share. While shares are currently trading at an 8% discount to the takeout price, which implies a risk that regulators break the deal, Stockton does not expect that to happen, the analyst tells investors. New from a few weeks ago about HMS Holdings (HMSY) being acquired, as well as this newly-announced deal, could be a positive for shares of hospital supplies cost and quality manager Premier (PINC), argues Stockton, who said that both deals could suggest the potential for a transaction at Premier still exists.
|Over a month ago|
Globus Medical awarded group purchasing agreement with Premier » 16:3712/0912/09/20
Globus Medical (GMED) was…
Globus Medical (GMED) was recently awarded a group purchasing agreement with Premier (PINC), one of the largest group purchasing organizations in the United States. The agreement covers Globus' Trauma Platform, which includes Anthem Plating, Autobahn Nailing, Arbor External Fixation, and Captivate Screw Platforms.
Berenberg starts four healthcare technology companies with Buy ratings » 06:4912/0812/08/20
OMCL, HCAT, CHNG, PINC
As previously reported,…
As previously reported, Berenberg analyst Iris Long initiated coverage of Omnicell (OMCL) with a Buy rating and $145 price target, started Health Catalyst (HCAT) with a Buy rating and $44 price target, initiated coverage of Change Healthcare (CHNG) with a Buy rating and $23 price target and started Premier (PINC) with a Buy rating and $42 price target. The analyst argues that each of the four companies is "uniquely positioned" to use digitization, automation and technology to take on the problems the U.S. healthcare system faces, including high costs and inefficiency.
Premier initiated with a Buy at Berenberg » 06:4212/0812/08/20
Berenberg analyst Iris…
Berenberg analyst Iris Long initiated coverage of Premier with a Buy rating and $42 price target.
Premier partners with Fresenius Kabi to help stabilize supply of heparin » 08:1511/1811/18/20
Premier has partnered…
Premier has partnered with Fresenius Kabi to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures. Heparin is an anticoagulant that prevents the formation of blood clots that can ultimately lead to venous and arterial thromboembolic events if not properly treated. The drug has been on the U.S. Food and Drug Administration, FDA, drug shortage list since 2017. However, shortages have been exacerbated recently, as research shows that between 25 and 40 percent of patients hospitalized with COVID-19 develop blood clots and require medications like heparin upon admission. These same patients remain at risk for clots up to 90 days post-discharge and that may extend the need for anticoagulation therapy.